To investigate whether CCL20 could differentiate between benign and early-stage malignancy, the CCL20 levels were subgroup analyzed by tumor stage, i.e., early stage (stages I and II) and advanced stage (stages III and IV). This evidence concerns the gene CCL20 and neoplasm.